Rankings
▼
Calendar
DAWN (Day One Biopharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena
DAWN
Day One Biopharmaceuticals, Inc.
Mkt Cap
$2B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$158M
Net Income (TTM)
-$107M
EPS (TTM)
-$1.04
Free Cash Flow (TTM)
-$108M
Gross Margin
89.1%
Op. Margin
-80.8%
Net Margin
-67.8%
FCF Margin
-68.0%
P/S Ratio (TTM)
14.0x
P/E Ratio (TTM)
—
YoY Rev Growth
+20.6%
Employees
—
Earnings Reports
▶
Q4 2025
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$0
-$89K
-$46M
Q2 23
$0
-$92K
-$49M
Q3 23
$0
-$99K
-$51M
Q4 23
$0
-$103K
-$60M
Q1 24
$0
-$116K
-$67M
Q2 24
$8M
$7M
-$115M
Q3 24
$94M
$92M
$30M
Q4 24
$29M
$26M
-$65M
Q1 25
$31M
$28M
-$41M
Q2 25
$34M
$30M
-$35M
Q3 25
$40M
$35M
-$24M
Q4 25
$54M
$48M
-$27M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
—
—
Q2 23
—
—
Q3 23
—
—
Q4 23
—
—
Q1 24
—
—
Q2 24
269.6x
—
Q3 24
21.7x
—
Q4 24
16.8x
—
Q1 25
13.6x
—
Q2 25
11.8x
—
Q3 25
16.5x
—
Q4 25
14.0x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$26M
-$26M
Q2 23
-$42M
-$43M
Q3 23
-$37M
-$40M
Q4 23
-$41M
-$41M
Q1 24
-$50M
-$50M
Q2 24
-$49M
-$66M
Q3 24
$51M
-$5M
Q4 24
-$30M
-$31M
Q1 25
-$59M
-$63M
Q2 25
-$25M
-$21M
Q3 25
-$6M
-$6M
Q4 25
-$14M
-$18M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$26K
Q2 23
$149K
Q3 23
$3M
Q4 23
$8K
Q1 24
$0
Q2 24
$17M
Q3 24
$56M
Q4 24
$1M
Q1 25
$4M
Q2 25
$3M
Q3 25
$0
Q4 25
$4M
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
—
+65.3%
Q2 23
—
+34.1%
Q3 23
—
+29.6%
Q4 23
—
+39.2%
Q1 24
—
+45.6%
Q2 24
—
+149.7%
Q3 24
—
+24.7%
Q4 24
—
+58.8%
Q1 25
—
+7.6%
Q2 25
+313.9%
-44.0%
Q3 25
-57.6%
-0.1%
Q4 25
+83.9%
-14.1%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$9M
—
Q2 23
$9M
—
Q3 23
$10M
—
Q4 23
$11M
—
Q1 24
$13M
—
Q2 24
$13M
159.1%
Q3 24
$12M
12.3%
Q4 24
$11M
37.8%
Q1 25
$13M
41.8%
Q2 25
$11M
32.1%
Q3 25
$10M
24.0%
Q4 25
$11M
20.6%
marketcaparena.com
OpEx Breakdown
R&D
SG&A
Quarter
R&D
SG&A
Q1 23
$28M
$18M
Q2 23
$32M
$17M
Q3 23
$33M
$18M
Q4 23
$37M
$22M
Q1 24
$40M
$26M
Q2 24
$92M
$30M
Q3 24
$34M
$29M
Q4 24
$62M
$30M
Q1 25
$40M
$29M
Q2 25
$36M
$29M
Q3 25
$31M
$28M
Q4 25
$41M
$34M
marketcaparena.com
Revenue Segments
Product
License
Quarter
Product
License
Q2 24
$8M
—
Q3 24
$20M
$74M
Q4 24
$29M
$253K
Q1 25
$31M
$258K
Q2 25
$34M
$346K
Q3 25
$39M
$1M
Q4 25
$53M
$884K
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$49M
$269M
$318M
Q2 23
$189M
$254M
$443M
Q3 23
$241M
$164M
$406M
Q4 23
$231M
$136M
$366M
Q1 24
$270M
$48M
$318M
Q2 24
$240M
$122M
$362M
Q3 24
$423M
$136M
$558M
Q4 24
$125M
$407M
$532M
Q1 25
$33M
$440M
$473M
Q2 25
$36M
$417M
$453M
Q3 25
$43M
$408M
$452M
Q4 25
$197M
$244M
$441M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
72M
-2.0%
Q2 23
75M
+4.2%
Q3 23
86M
+14.7%
Q4 23
87M
+1.5%
Q1 24
87M
-0.6%
Q2 24
87M
+0.5%
Q3 24
97M
+11.3%
Q4 24
94M
-3.4%
Q1 25
103M
+9.7%
Q2 25
103M
+0.3%
Q3 25
103M
+0.3%
Q4 25
103M
+0.0%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 19
—
—
FY 20
—
—
FY 21
$0
55
FY 22
$0
121
FY 23
$0
155
FY 24
$725K
181
FY 25
$791
200K
marketcaparena.com